相关实验视频
Updated: Jul 18, 2026

05:05
Dissection of Human Vitreous Body Elements for Proteomic Analysis
Published on: January 23, 2011
31.8K
在死后药物分析中比较玻璃体液和血液矩阵
Erin B Divito1, Jedediah I Bondy2, Zachary J DiPerna2
1Department of Chemistry, University of Pittsburgh at Greensburg, Greensburg, PA 15601, United States.
Journal of analytical toxicology
|March 4, 2025
概括
玻璃体液 (VIT) 显示为死后药物分析的前景,提供了一个稳定的矩阵. 然而,对于某些分析物,如芬太尼及其代谢物,全血分析仍然是最佳的.
科学领域:
- 法医毒理学 法医毒理学
- 尸体解剖后的分析
- 分析化学 分析化学
背景情况:
- 周围血液是死后毒理学的标准.
- 玻璃体液 (VIT) 可能由于抗死后再分配而提供更好的保存.
- 了解替代矩阵对于准确的毒理学评估至关重要.
研究的目的:
- 评价玻璃体液 (VIT) 作为对6 - 乙吗啡,吗啡,可卡因,黄,芬太尼和诺芬太尼的死后分析的矩阵.
- 为了比较VIT和外围血液之间的药物检测频率和度.
- 为了确定VIT分析与传统血液分析的实用性.
主要方法:
- 来自122例死后病例的对外周围血液和玻璃体液 (VIT) 样本的分析.
- 对特定滥用药物及其代谢物的毒理学分析.
- 两个矩阵之间的药物度的统计相关性.
主要成果:
- 玻璃体液 (VIT) 是一种可行的矩阵,用于检测几个滥用药物及其代谢物.
- 在VIT中的药物度并不总是与全血度保持最佳相关性.
- 分析剂适合性的差异可能是由于生理化学性质和药理动力学.
结论:
- 玻璃体液 (VIT) 分析是特定分析物的死后毒理学中一个有价值的工具.
- 对于某些药物,包括芬太尼及其代谢物,全血分析仍然优越.
- 矩阵的选择取决于具体的分析物和药理动力学的考虑.
相关概念视频
Drug Concentrations: Measurements
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Plasma —...
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...

